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Abstract. According to the ToGA trial, HER2 has been shown 
to be predictive for the success of treatment with trastuzumab 
in advanced gastric cancer (AGC). A number of studies have 
analyzed HER‑2/neu overexpression in gastric carcinoma and 
identified the rate of HER2 positivity to be markedly varied. 
To date, the prevalence of HER2 overexpression in Sicilian 
people with AGC is unknown. Therefore, in the present study, 
a retrospective immunohistochemical analysis of HER2 was 
performed in a cohort of 304 AGC samples that were obtained 
from the archives of 10 Sicilian anatomopathological diagnostic 
units in order to verify the positive rate of HER2‑positive cases. 
Furthermore, the characteristics of histotype, grade, stage and 
Ki‑67 expression were also analyzed. HER2 overexpression was 
encountered in 17.43% of all the gastric adenocarcinomas, which 
was consistent with the results that have been reported elsewhere 
in the literature. A progressive increase in HER2 overexpression 
was observed, from the poorly cohesive histotype to the tubular 
adenocarcinomas and gastric hepatoid adenocarcinomas. HER2 
overexpression was significantly associated with a high grade, 
advanced stage and high Ki‑67 labeling index. Further investi‑
gations performed jointly by pathologists and oncologists within 
the geographical area of the present study should confirm that 
the association of trastuzumab with chemotherapy results in an 
improvement of survival in patients with AGC.
Introduction
HER‑2 gene amplification and protein overexpression have been 
indicated as the targets for therapy with the anti‑HER2 human‑
ized monoclonal antibody, trastuzumab, in various cancers (1‑9). 
In these studies, a wide range of HER‑2 expression has been 
described with controversial data (9). However, in an open‑label 
international phase 3 randomized controlled trial that was under‑
taken in 122 centers within 24 countries, patients with advanced 
gastric or gastroesophageal junction carcinomas were studied in 
order to verify whether the tumors demonstrated an overexpres‑
sion of HER‑2 protein, as detected by immunohistochemistry 
or gene amplification using fluorescence in situ hybridization 
(FISH) (10). In particular, the randomized ToGA study revealed 
a 26% reduction in the risk of mortality when trastuzumab 
was added to the chemotherapy regime (hazard ratio, 0.74) for 
treating advanced gastric carcinomas (AGCs) (10). Although the 
reported rates of HER‑2 overexpression appear to be variable, 
there is a general agreement with regard to a higher HER‑2 posi‑
tivity in gastroesophageal junction cancer (24‑35%) compared 
with gastric carcinoma (9.5‑21%) (11‑13). Furthermore, common 
gastric tumors that are classified as intestinal types are more 
likely to be HER‑2 positive (16‑34%) compared with diffuse 
(2‑7%) or mixed (5‑20%) types (11‑12,14,15), although certain 
aggressive variants, including hepatoid gastric carcinomas, have 
been shown to exhibit the highest HER‑2 immunoreactivity (16).
To date, no data with regard to the HER2 status in AGCs 
are available from the geographical area of a Mediterranean 
region, such as Sicily, though a mean decrease of 29.7% has 
been registered in the comparison between 1993‑1995 and 
2003‑2005, independently from the gender of patients (17). 
Therefore, the present study analyzed the HER2 status in a 
HER2 status in advanced gastric carcinoma:  
A retrospective multicentric analysis from Sicily
A. IENI1,2,  V. BARRESI1,  G. GIUFFRÈ1,  R.A. CARUSO1,  S. LANZAFAME3,  L. VILLARI4,  
E. SALOMONE4,  E. ROZ5,  D. CABIBI6,  V. FRANCO6,  G. CERTO7,  A. LABATE7,  C. NAGAR8,  
E. MAGLIOLO2,  B. BROGGI9,  C. FAZZARI10,  F. ITALIA11  and  G. TUCCARI1,12
1Department of Human Pathology, University of Messina; 2Pathological Anatomy Unit, ASP 5 Messina, Messina;  
3Department of Anatomy, Diagnostic Pathology, Legal Medicine and Public Health, University of Catania;  
4Pathological Anatomy Unit, Vittorio Emanuele II University Hospital, Catania; 5Health Home Service ‘La Maddalena’; 
6Department of Human Pathology, University of Palermo, Palermo; 7Health Home Service ‘IOMI‑Cappellani’, Messina; 
8Pathological Anatomy Unit, ASP 6 Palermo, Palermo; 9Pathological Anatomy Unit, ASP 8 Siracusa, Siracusa;  
10Humanitas Center of Oncology, Catania; 11Oncopathology Laboratory, Floridia, Siracusa;  
12Cytodiagnostics and Molecular Biology Interdepartmental programme, 
‘Polyclinic G Martino’ University Hospital, Messina, Sicily, Italy
Received March 22, 2013;  Accepted October 2, 2013
DOI: 10.3892/ol.2013.1611
Correspondence to: Professor Giovanni Tuccari, Department of 
Human Pathology, Section of Pathological Anatomy, ‘Polyclinic 
G Martino’ University Hospital, Via Consolare Valeria, Messina 
I‑198125, Italy
E‑mail: tuccari@unime.it; giovannituccari@yahoo.it
Key words: HER2 status, gastric adenocarcinoma, trastuzumab, 
Sicily
LENI et al:  HER2 STATUS IN SICILIAN ADVANCED GASTRIC CANCER2
cohort of 304 surgical cases of advanced/metastatic gastric 
carcinomas that were obtained from the archives of 10 Sicilian 
anatomopathological units, in order to verify the positive rate 
of HER2‑positive cases, taking into consideration the charac‑
teristics of the histotype, grade, stage and Ki‑67 expression.
Materials and methods
Samples. A total of 304 surgically‑treated patients with gastric 
adenocarcinoma, who were not administered neoadjuvant 
chemotherapy, were selected from the files of 10 Sicilian anato‑
mopathological diagnostic units. The patients who succumbed 
within 30 days of surgery (post‑operative mortality) were 
excluded from the study. Informed consent was obtained 
from all the patients that were studied. Furthermore, the 
study was purely observational and no medical interventions 
were performed. Approval for the study was obtained from 
the Local Ethics Committees of the University of Messina 
(Messina, Italy), University of Catania (Catania, Italy) and 
University of Palermo (Palermo, Italy).
The tumors were taken from an equal number of patients, 
183 of which were male and 121 of which were female, with 
a mean age of 68.3 years (range, 41‑93 years). The tumor was 
localized in the antrum of the stomach in 151 patients, the 
body in 136 and the fundus in 17, 11 of which were located 
at the gastroesophageal junction. All the gastric surgical 
specimens were fixed in 10% neutral formalin for 24‑48 h 
and paraffin embedded at 56˚C. The histotypes, according 
to the WHO classification (18), grade and staging were also 
available. A total of 183 tubular/papillary/mucinous adeno‑
carcinomas (PTM adenocarcinomas), 98 poorly cohesive 
carcinomas and 23 cases of rare variants of adenocarcinomas, 
including 14 hepatoid adenocarcinomas (HACs) and nine 
mitochondrion‑rich adenocarcinomas (MRCs), were analyzed. 
HACs are identified as adenocarcinomas that exhibit only a 
solid pattern of large polygonal eosinophilic cells, without foci 
of tubular/papillary differentiated areas and a clear cytoplasm 
within the cells. This hepatoid variant was validated by an 
immunohistochemical (IHC) analysis for α‑1‑fetoprotein and 
HepPar1 antisera. The MRCs were morphologically charac‑
terized by ultrastructural observations, including junctional 
complexes and desmosomes with numerous mitochondria in 
the cytoplasm of the tumor cells, which were mainly concen‑
trated in the supranuclear region. This oncocytic variant was 
validated by an immunohistochemical analysis for anti‑mito‑
chondrial antibody. 
HER2 determination. HER‑2 status was evaluated by IHC 
immunostaining on 3‑µm thick sections that were mounted 
on silane‑coated slides using HercepTest™ (Dako, Glostrup, 
Denmark). An antigen retrieval pre‑treatment was performed 
by three changes in 0.01 M citrate buffer (pH 6.0) in a 
microwave oven at 750 W. Each immunostained section was 
evaluated by the following score: 0, absent staining, 1+, faint 
and discontinuous membranous staining in <10% of neoplastic 
elements; 2+, light to moderate lateral, basolateral or complete 
membranous staining in >10% of neoplastic elements; and 
3+, strong, intense lateral, basolateral or complete staining 
in >10% of neoplastic elements. For reproducible intensity 
scoring, it is advised to apply the magnification rule algorithm, 
which has been previously described (15). All the cases that 
were considered equivocal (2+) were further assessed using 
the FISH test (pharmDx; Dako) in three reference laborato‑
Figure 1. (A) Neoplastic elements of the poorly cohesive histotype showing 
HER2 negativity (x400). (B) Light‑moderate incomplete HER2 2+ staining 
was appreciated in the tubular areas of the adenocarcinomas (x400). 
(C) Strong intense complete and diffuse HER2 staining was encountered in 
AGC at a lower magnification (x150). (D) Neoplastic thrombi showing 3+ 






ries. Gene amplification was recorded when the HER2:CEP17 
signal ratio was >2.0. 
Additional immunohistochemistry. The HAC samples were 
tested using polyclonal rabbit anti‑human α‑1‑fetoprotein (clone 
A000802‑29) and monoclonal mouse anti‑human hepatocyte 
(Clone OCH1E5) (Dako). A strongly positive immunostaining 
pattern that was diffuse or focally granular was encountered 
in the cytoplasm of the neoplastic cells. The MRC samples 
exhibited a positive immunostaining pattern that was local‑
ized in the cellular supranuclear region by mouse polyclonal 
anti‑human mitochondria antibody (clone MTCO2). 
In parallel sections that were obtained from the same tissue 
blocks, Ki‑67 antigen was unmasked by the previously cited 
retrieval procedure. Ki‑67 antiserum (clone MIB‑1; w.d. 1:50; 
Dako) was applied for 30 min at room temperature. The Ki‑67 
labeling index (LI) was calculated as the mean percentage 
by counting the stained nuclei of 1,000 tumor cells in three 
representative neoplastic fields. All degrees of nuclear staining 
intensity were taken into consideration. The median Ki‑67 LI 
value (30%) was utilized as the cut‑off point to define low and 
high Ki‑67 expression.
Statistical analysis. Statistical analysis was performed by 
χ2 test to analyze the associations between HER2 status and 
the clinicopathological parameters. P<0.05 was considered to 
indicate a statistically significant difference. The data were 
analyzed using the SPSS package, version 6.1.3 (SPSS, Inc., 
Chicago, IL, USA).
Results
Taking into consideration the HER2‑positive rate, a range of 
variability of 7.69‑21.7% was identified in the various anato‑
mopathological units, with a mean value of 17.43%. HER2 
overexpression was encountered in 53 of the total AGC cases, 
independently from the histotype. In detail, a progressive 
increase in the oncoprotein immunoreactivity was observed, 
from the frequently HER2‑negative poorly cohesive histotype 
(3.5%; Fig. 1A) to MRCs (11.1%), tubular/papillary adenocar‑
cinomas (31.3%; Fig. 1B and C) and HACs (42.9%). HER2 
immunoreactivity was also evident in the angiolymphatic 
neoplastic thrombi (Fig. 1D). Finally, HER2 overexpression 
was significantly associated with a high grade (P=0.011), 
advanced stage (P=0.002) and high Ki‑67 LI value (P=0.015).
Discussion
Numerous studies have documented HER2 amplification 
in AGC, although the association with the survival or TNM 
status of patients remains debatable (15,19‑24). Giuffrè et al 
previously encountered a HER2 overexpression rate of 21.10% 
in a smaller cohort of gastric adenocarcinomas that were 
obtained from a single pathological unit (16), which is consis‑
tent with the results that have been reported elsewhere in the 
literature (11,19,21,25‑28), in which the mean HER2 positivity 
rate, using FISH or chromogenic in situ hybridization, was 
19.2% (range, 7.1‑42.6%) (25). In the present study, which 
analyzed a larger sample of AGC from a number of varying 
institutions within the same geographical area, HER2 over‑
expression was identified in 53 (17.43%) of the 304 samples 
of AGC. This latter rate was marginally lower than the 
mean HER2 positivity that has been previously cited (25). 
However, taking into consideration only the IHC studies that 
are available in the literature, which have been performed on 
3264 AGC samples (25), the mean HER2‑positive rate was 
17.6% (range, 6.8‑34.0%), which is equivalent to the result of 
the present study. Consequently, a non‑significant variation 
in HER2 determination should be attributed to the subjective 
interpretation, as well as the scoring of the immunohisto‑
chemical results, of the AGC samples that were observed in 
the geographical area of the present study. The achieved 
reproducibility between the various laboratories within the 
present study was predominantly due to standardized fixation 
methods and times for the tissue samples. Furthermore, the 
application of the magnification rule (15) in the IHC observa‑
tions and the determination of HER2 gene amplification by 
FISH, which was performed exclusively in three well‑trained 
anatomopathological institutions, have further contributed to 
reduce the inter‑observer variability and to guarantee an accu‑
rate evaluation of the HER2 status. However, the requirement 
to improve HER2 expression and gene amplification in gastric 
cancer has been also been indicated by a consortium of expert 
pathologists in other European countries (15,25,29), which is 
similar to the retrospective purpose of the present study. 
In the present study, a progressive increase in HER2 
immunoreactivity was observed, from the poorly cohesive 
histotype (3.5%) to MRCs (11.1%), tubular/papillary adeno‑
carcinomas (31.3%) and HACs (42.9%). Furthermore, HER2 
overexpression was also significantly associated with a high 
grade, stage and Ki‑67 LI value. Thus, the HER2 status may 
represent an additional morphological parameter that is able to 
affect the mortality of patients with gastric cancer. Although 
there is a possibility that HER2 overexpression in AGC may 
emerge as an independent prognostic parameter, this requires 
clinical oncological outcomes that are currently unavailable 
for the present casuistry. However, in a previous multivariate 
analysis, HER2 overexpression was identified as an indepen‑
dent unfavorable prognostic variable for adenocarcinomas as a 
whole and also for the unusual hepatoid variant (16).
In conclusion, further investigations that are jointly 
performed by pathologists and oncologists present within 
the geographical area of the current study should confirm 
that the association between trastuzumab and chemotherapy 
determines an improvement in survival for patients with 
AGC showing amplification or overexpression of the HER2 
protein.
References
 1. Ross JS and McKenna BJ: The HER‑2/neu oncogene in tumors of 
the gastrointestinal tract. Cancer Invest 19: 554‑568, 2001.
 2. Latif Z, Watters AD, Bartlett JM, et al: Gene amplification and 
overexpression of HER2 in renal cell carcinoma. BJU Int 89: 5‑9, 
2002.
 3. Leyland‑Jones B: Trastuzumab therapy for the metastatic patient: 
does the primary match? Ann Oncol 13: 993‑994, 2002.
 4. Oxley JD, Winkler MH, Gillatt DA and Peat DS: Her‑2/neu 
oncogene amplification in clinically localised prostate cancer. 
J Clin Pathol 55: 118‑120, 2002.
 5. Haddad R, Colevas AD, Krane JF, et al: Herceptin in patients 
with advanced or metastatic salivary gland carcinomas. A 
phase II study. Oral Oncol 39: 724‑727, 2003.
LENI et al:  HER2 STATUS IN SICILIAN ADVANCED GASTRIC CANCER4
 6. Latif Z, Watters AD, Dunn I, et al: HER2/neu gene amplification 
and protein overexpression in G3 pT2 transitional cell carcinoma 
of the bladder: a role for anti‑HER2 therapy? Eur J Cancer 40: 
56‑63, 2004.
 7. Hansel DE, Ashfaq R, Rahman A, et al: A subset of pancreatic 
adenocarcinomas demonstrates coamplification of topoisomerase 
IIalpha and HER2/neu: use of immunolabeling and multicolor 
FISH for potential patient screening and treatment. Am J Clin 
Pathol 123: 28‑35, 2005.
 8. Ugocsai K, Mándoky L, Tiszlavicz L and Molnár J: Investigation 
of HER2 overexpression in non‑small cell lung cancer. Anticancer 
Res 25: 3061‑3066, 2005.
 9. Tapia C, Savic S, Wagner U, et al: HER2 gene status in primary 
breast cancers and matched distant metastases. Breast Cancer 
Res 9: R31, 2007.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial 
Investigators: Trastuzumab in combination with chemotherapy 
versus chemotherapy alone for treatment of HER2‑positive 
advanced gastric or gastro‑oesophageal junction cancer (ToGA): 
a phase 3, open‑label, randomised controlled trial. Lancet 376: 
687‑697, 2010.
11. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER‑2 
in gastric carcinoma: association with Topoisomerase IIalpha 
gene amplification, intestinal type, poor prognosis and sensitivity 
to trastuzumab. Ann Oncol 16: 273‑278, 2005.
12. Hede K: Gastric cancer: trastuzumab trial results spur search for 
other targets. J Natl Cancer Inst 101: 1306‑1307, 2009.
13. Moelans CB, Milne AN, Morsink FH, et al: Low frequency of 
HER2 amplification and overexpression in early onset gastric 
cancer. Cell Oncol (Dordr) 34: 89‑95, 2011.
14. Gravalos C and Jimeno A: HER2 in gastric cancer: a new 
prognostic factor and a novel therapeutic target. Ann Oncol 19: 
1523‑1529, 2008.
15. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in 
gastric cancer‑guideline validation and development of stan‑
dardized immunohistochemical testing. Virchows Arch 457: 
299‑307, 2010.
16. Giuffrè G, Ieni A, Barresi V, et al: HER2 status in unusual histo‑
logical variants of gastric adenocarcinomas. J Clin Pathol 65: 
237‑241, 2012.
17. Crocetti E and AIRTUM Working Group: Incidence and 
mortality cancer trends of the Italian Network of Cancer 
Registries (AIRTUM), 1998‑2005. Epidemiol Prev 33 (Suppl 1): 
36‑37, 2009.
18. Bosman FT, Carneiro F, Hruban RH and Theise ND (eds): WHO 
Classification of Tumours of the Digestive System. 4th edition. 
IARC, Lyon, France, 2010.
19. Albarello L, Pecciarini L and Doglioni C: HER2 testing in 
gastric cancer. Adv Anat Pathol 18: 53‑59, 2011.
20. Barros‑Silva JD, Leitão D, Afonso L, et al: Association of 
ERBB2 gene status with histopathological parameters and 
disease‑specific survival in gastric carcinoma patients. Br 
J Cancer 100: 487‑493, 2009.
21. Marx AH, Tharun L, Muth J, et al: HER‑2 amplification is highly 
homogenous in gastric cancer. Hum Pathol 40: 769‑777, 2009.
22. Grabsch H, Sivakumar S, Gray S, et al: HER2 expression 
in gastric cancer: Rare, heterogeneous and of no prognostic 
values ‑ conclusions from 924 cases of two independent series. 
Cell Oncol 32: 57‑65, 2010. 
23. Yan B, Yau EX, Bte Omar SS, et al: A study of HER2 gene 
amplification and protein expression in gastric cancer. J Clin 
Pathol 63: 839‑842, 2010.
24. Jørgensen JT: Targeted HER2 treatment in advanced gastric 
cancer. Oncology 78: 26‑33, 2010.
25. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 
scoring system for gastric cancer: results from a validation study. 
Histopathology 52: 797‑805, 2008.
26. Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene ampli‑
fication assessed by fluorescence in situ hybridization and HER2 
protein expression assessed by immunohistochemistry in gastric 
cancer. Oncol Rep 15: 65‑71, 2006.
27. Kumashiro Y, Yao T, Aishima S, et al: Hepatoid adenocarcinoma 
of the stomach: histogenesis and progression in association with 
intestinal phenotype. Hum Pathol 38: 857‑863, 2007.
28. Gálvez‑Muñoz E, Gallego‑Plazas J, Gonzalez‑Orozco V, et al: 
Hepatoid adenocarcinoma of the stomach ‑ a different histology 
for not so different gastric adenocarcinoma: a case report. Int 
Semin Surg Oncol 6: 13, 2009.
29. Jouret‑Mourin A, Hoorens A, De Hertogh G, et al: Analysis of 
HER2 expression and gene amplification in adenocarcinoma of 
the stomach and the gastro‑oesophageal junction: rationale for the 
Belgian way of working. Acta Gastroenterol Belg 75: 9‑13, 2012.
